Lentivirally Redirected CD123 Autologous T Cells in AML

Acute Myeloid Leukemia, in Relapse Clinical Trial

Official title:

Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD123 Linked to TCRζ and 4-1BB Signaling Domains in Subjects With Refractory or Relapsed Acute Myeloid Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03766126
• Other study ID #: 831619 (UPCC 35418)
• Status: Recruiting
• Phase: Phase 1
• Start date: December 6, 2018
• Est. completion date: December 3, 2033

Study information

• Verified date: April 2024
• Source: University of Pennsylvania
• Contact: EmergingMed
• Phone: 855-216-0098
• Email: PennCancerTrials[@]careboxhealth.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in Acute Myeloid Leukemia (AML) subjects.

Description:

This is a Phase 1 study to determine the safety, feasibility, and efficacy of CART123 cells following lymphodepleting chemotherapy in patients with relapsed/refractory AML. Subjects will be treated with a split dosing approach of CART123 cells (10% Day 0; 30% Day 1; 60% Day 2) for Cohort 1a/1b or a single IV administration of CART123 cells for Cohort 2. The total dose administered to each subject will be based on body weight obtained at the time of apheresis. Thus, the target total transduced dose, preceded by lymphodepleting chemotherapy, is 1-2x10^6 CART123 cells/kg for Cohort 1a, 5x10^6 CART123 cells/kg for Cohort 1b, or 2x10^6 CART-123 cells/kg for Cohort 2. The protocol-specified minimum acceptable dose for infusion is 1x10^5 CART123 cells/kg for all cohorts. It is recommended per routine clinical care, that all subjects with marrow aplasia at Day 28+/-5 undergo allogeneic hematopoietic cell transplantation (alloHCT) as a rescue strategy. If required, this procedure will be performed as part of routine care, outside of the scope of this research study, however subjects will continue to be followed on study. All subjects should therefore have a previously identified stem cell donor in order to participate in this study. Please see Section 6.8 for additional details. All subjects will be followed monthly for up to 6 months post the first CART123 cell infusion (Day 0). Thereafter subjects will be transitioned into LTFU for up to 15 years post infusion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: December 3, 2033
• Est. primary completion date: August 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female subjects 18 years of age or older

2. Subjects with active acute myeloid leukemia (AML) with no available curative treatment

options using currently available therapies. Specifically:

1. AML that has not achieved a complete remission or morphologic leukemia free state by ELN criteria (Döhner et al., 2017 Blood, 129(4):424-447); partial remission or

refractory disease (including primary refractory) are eligible. Or:

2. AML relapsed following allogeneic stem cell transplantation (including MDS evolved to AML post-allogeneic stem cell transplantation). Note: morphologic relapse is not required; persistent/recurrent disease-associated molecular, phenotypic or cytogenetic abnormalities (measurable residual disease, MRD) at any time after allogeneic HCT is eligible

3. Subjects with relapsed disease after prior transplant must meet one of the following:

a. Subjects with relapsed disease after prior allogeneic HCT (myeloablative or non-myeloablative) will be eligible if they meet all other inclusion criteria and i. Have no residual donor cells (by STR analysis on 2 occasions separated by at least 1 month), OR: ii. Donor cells are present but there is no active GVHD (>Gr II), subject does not require systemic immunosuppression and is more than 3 months from transplant, and at least 1 month off GVHD prophylaxis. b. Subjects with relapsed disease after prior autologous or syngeneic HCT will be eligible if they meet all other inclusion criteria and it has been more than 3 months from transplant.

4. Subjects must have a suitable stem cell donor available who may donate cells in the event the subject needs to undergo an allogeneic HCT. Donor may be matched or mismatched and must be found to be suitable according to the institution's standard criteria; donors must be fully cleared to proceed as the donor.

5. Satisfactory organ functions:

1. Creatinine = 1.6 mg/dl

2. ALT/AST must be =5 x upper limit of normal unless related to disease

3. Direct bilirubin or total bilirubin < 2.0mg/dl, unless subject has Gilbert's syndrome (=3.0 mg/dL);

4. Left ventricular ejection fraction = 40% as confirmed by ECHO/MUGA

6. ECOG Performance status 0-2.

7. Written informed consent is given.

8. No contraindications for leukapheresis.

9. Subjects of reproductive potential must agree to use acceptable birth control methods (as described in protocol Section 4.3).

Exclusion Criteria:

1. Pregnant or lactating (nursing women) women.

2. Patients with relapsed AML with t(15:17).

3. HIV infection.

4. Active hepatitis B or hepatitis C infection.

5. Concurrent use of systemic steroids or immunosuppressant medications. Recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary. For additional details regarding use of steroids while on study, please see Section 5.5.

6. Any uncontrolled active medical disorder that would preclude participation as outlined.

7. Subjects with signs or symptoms indicative of CNS involvement. A CNS evaluation should be performed as clinically appropriate to rule out CNS involvement.

8. Known history of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40).

9. Class III/IV cardiovascular disability according to the New York Heart Association Classification (see Appendix 3).

10. Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to leukemia or previous leukemia treatment.

11. Subjects with clinically apparent arrhythmia, or arrhythmias that are not stable on medical management, within 2 weeks of the Screening/Enrollment visit.

12. Patients with any prior history of myeloproliferative neoplasm.

13. Patients with the JAK2 V617F mutation by PCR or next generation sequencing.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia, Adult
• Acute Myeloid Leukemia, in Relapse
• Acute Myeloid Leukemia, Refractory
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Biological:
• CART123 cells; cyclophosphamide; fludarabine
CART123 cells following lymphodepleting chemotherapy in patients with relapsed/refractory AML. Subjects will be treated with a split dosing approach of CART123 cells (10% Day 0; 30% Day 1; 60% Day 2) for Cohort 1a/1b or a single IV administration of CART123 cells for Cohort 2. The total dose administered to each subject will be based on body weight obtained at the time of apheresis. Thus, the target total transduced dose, preceded by lymphodepleting chemotherapy, is 1-2x10^6 CART123 cells/kg for Cohort 1a, 5x10^6 CART123 cells/kg for Cohort 1b, or 2x10^6 CART-123 cells/kg for Cohort 2. The protocol-specified minimum acceptable dose for infusion is 1x10^5 CART123 cells/kg.

Locations

Country	Name	City	State
United States	University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety profile of CART123 cells by monitoring the frequency and severity of adverse events assessed by the National Cancer Institute (NCI) - Common Toxicity Criteria (v5.0)	Assess the safety of CART123 cells in AML subjects following lymphodepletion with cyclophosphamide + fludarabine.	5 years
Primary	Evaluate the percentage of manufacturing products that do not meet release criteria for vector transduction efficiency, T cell product purity, viability, sterility.	Evaluate the percentage of manufacturing products that do not meet release criteria for vector transduction efficiency, T cell product purity, viability, sterility.	5 year
Secondary	Estimation of CART123 efficacy by evaluation of OS and PFS of subjects at protocol defined intervals which receive at least one infusion of CART123 cells	Estimate the efficacy of at least 1 dose of CART123 cells in AML subjects	15 years
Secondary	Overall Survival (OS) as percent of subjects surviving at protocol defined time points.	Overall survival (OS) and progression-free survival (PFS)	15 years
Secondary	Progression-free survival (PFS) as percent of subjects surviving without disease progression at protocol defined time points		15 years
Secondary	Duration of response (DOR)	Duration of response (DOR)	15 years
Secondary	Necessity of rescue bone marrow transplant	Need for rescue allogeneic hematopoietic cell transplantation (alloHCT)	15 years